Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination

The authors would like to thank the following funding agencies for their support: Paracelsus Medical University PMU-FFF Long-Term Fellowship L-12/01/001-RIV (to and Stand-Alone Grant E-12/15/077-RIT (both to F.J.R.); Chilean Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) FONDECYT Program Regular Grant No 1161787 (to F.J.R.), Regular Grant No 1141015 (to L.F.B.); Chilean CONICYT PCI Program Grant No REDES170233 (to F.J.R.), Grant No REDES180139 and Grant No REDI170037; Chilean CONICYT FONDEFIDeA Program Grant No ID17AM0043 (to M.E.S. and F.J.R.); European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreements N HEALTH-F2-2011-278850 (INMiND) and HEALTH-F2-2011-279288 (IDEA). The work in the Kury laboratory was supported by the German Research Foundation (DFG; KU1934/2_1, KU1934/5-1) and the Christiane and Claudia Hempel Foundation for clinical and iBrain. The work in the Franklin laboratory was supported by grants from the UK Multiple Sclerosis Society and the Adelson Medical Research Foundation, and a core support grant from the Wellcome Trust and MRC to the Wellcome-MRC Cambridge Stem Cell Institute. In addition, the present work was supported by the state of Salzburg (to L.A.). We thank Armin Schneider, Sygnis Pharma AG Heidelberg, Germany, for the MBP promoter construct. We disclose any conflict of interest.